Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329


Challenges and solutions in patient treatment strategies for stage II colon cancer.

Fotheringham S, Mozolowski GA, Murray EMA, Kerr DJ.

Gastroenterol Rep (Oxf). 2019 Jun;7(3):151-161. doi: 10.1093/gastro/goz006. Epub 2019 Mar 11. Review.


Narrative Identity Reconstruction as Adaptive Growth During Mental Health Recovery: A Narrative Coaching Boardgame Approach.

Kerr DJR, Deane FP, Crowe TP.

Front Psychol. 2019 May 8;10:994. doi: 10.3389/fpsyg.2019.00994. eCollection 2019.


Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for Health.

Baines LS, Kerr DJ.

J Epidemiol Glob Health. 2018 Dec;8(3-4):236. doi: 10.2991/j.jegh.2018.07.001. No abstract available.


Formation of Highly Substituted Indenes through Acid Promoted Cyclodehydration with Nucleophile Incorporation.

Dillon AS, Kerr DJ, Flynn BL.

J Org Chem. 2019 Mar 1;84(5):2756-2767. doi: 10.1021/acs.joc.8b03042. Epub 2019 Feb 12.


Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.

Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang QW, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR; Written on behalf of AME Colorectal Cancer Cooperative Group.

Int J Cancer. 2019 May 1;144(9):2161-2168. doi: 10.1002/ijc.32044. Epub 2019 Jan 9.


Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.

Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE.

J Natl Cancer Inst. 2018 Dec 1;110(12):1400-1408. doi: 10.1093/jnci/djy063.


The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar RAEM, Kerr DJ, Mesker WE.

J Surg Oncol. 2018 Apr;117(5):1043-1048. doi: 10.1002/jso.24998. Epub 2018 Feb 15.


Chromatin organisation and cancer prognosis: a pan-cancer study.

Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE.

Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3.


Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, Kostolomov I, Nesheim JA, Askautrud HA, Nesbakken A, Lothe RA, Svindland A, Shepherd N, Novelli M, Johnstone E, Tomlinson I, Kerr R, Kerr DJ.

Ann Oncol. 2018 Mar 1;29(3):616-623. doi: 10.1093/annonc/mdx794.


Multistereocenter-Containing Cyclopentanoids from Ynamides via Oxazolidinone-Controlled Nazarov Cyclization.

Manchala N, Law HYL, Kerr DJ, Volpe R, Lepage RJ, White JM, Krenske EH, Flynn BL.

J Org Chem. 2017 Jul 7;82(13):6511-6527. doi: 10.1021/acs.joc.7b00082. Epub 2017 Jun 13.


Is sidedness prognostically important across all stages of colorectal cancer?

Kerr DJ, Domingo E, Kerr R.

Lancet Oncol. 2016 Nov;17(11):1480-1482. doi: 10.1016/S1470-2045(16)30431-4. No abstract available. Erratum in: Lancet Oncol. 2016 Dec;17 (12 ):e519.


Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ.

Lancet Oncol. 2016 Nov;17(11):1543-1557. doi: 10.1016/S1470-2045(16)30172-3. Epub 2016 Sep 19.


Aberrant hippocampal Atp8a1 levels are associated with altered synaptic strength, electrical activity, and autistic-like behavior.

Kerr DJ, Marsillo A, Guariglia SR, Budylin T, Sadek R, Menkes S, Chauhan A, Wen GY, McCloskey DP, Wieraszko A, Banerjee P.

Biochim Biophys Acta. 2016 Sep;1862(9):1755-65. doi: 10.1016/j.bbadis.2016.06.005. Epub 2016 Jun 7.


Strategies for Sustainable Cancer Care.

Kerr DJ, Jani A, Gray SM.

Am Soc Clin Oncol Educ Book. 2016;35:e11-5. doi: 10.14694/EDBK_156142.


Connecting the Global Cancer Community.

Kerr DJ.

J Glob Oncol. 2015 Oct 28;1(2):47-48. doi: 10.1200/JGO.2015.001503. eCollection 2015 Dec. No abstract available.


Should We Adapt Existing Quality Systems for Use in Low- and Middle-Income Countries?

Kerr DJ.

J Oncol Pract. 2015 Sep;11(5):370-1. doi: 10.1200/JOP.2015.006577. No abstract available.


Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments.

Bell DJ, Kerr DJ.

Expert Opin Drug Metab Toxicol. 2015;11(9):1341-4. doi: 10.1517/17425255.2015.1055247. Epub 2015 Jun 22.


Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.

McGregor MJ, Fadhil W, Wharton R, Yanagisawa Y, Presz M, Pritchard A, Womack C, Dutton S, Kerr RS, Kerr DJ, Johnstone EC, Ilyas M.

Anticancer Res. 2015 Mar;35(3):1641-5.


Clinical cancer research: the past, present and the future.

DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ.

Nat Rev Clin Oncol. 2014 Nov;11(11):663-9. doi: 10.1038/nrclinonc.2014.153. Epub 2014 Sep 23. Review.


Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.

Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom KJ, Salmon A, D'Silva O, Betteridge KB, Williams AC, Kerr DJ, Salmon AH, Oltean S, Midgley RS, Ladomery MR, Harper SJ, Varey AH, Bates DO.

Mol Oncol. 2015 Jan;9(1):167-78. doi: 10.1016/j.molonc.2014.07.017. Epub 2014 Aug 20.


Policy: EU data protection regulation--harming cancer research.

Kerr DJ.

Nat Rev Clin Oncol. 2014 Oct;11(10):563-4. doi: 10.1038/nrclinonc.2014.148. Epub 2014 Sep 2.


Health diplomacy: a new approach to the Muslim world?

Suleman M, Ali R, Kerr DJ.

Global Health. 2014 Jun 13;10:50. doi: 10.1186/1744-8603-10-50.


Building capacity for sustainable research programmes for cancer in Africa.

Adewole I, Martin DN, Williams MJ, Adebamowo C, Bhatia K, Berling C, Casper C, Elshamy K, Elzawawy A, Lawlor RT, Legood R, Mbulaiteye SM, Odedina FT, Olopade OI, Olopade CO, Parkin DM, Rebbeck TR, Ross H, Santini LA, Torode J, Trimble EL, Wild CP, Young AM, Kerr DJ.

Nat Rev Clin Oncol. 2014 May;11(5):251-9. doi: 10.1038/nrclinonc.2014.37. Epub 2014 Mar 11. Review.


Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R.

J Clin Oncol. 2013 Dec 1;31(34):4297-305. doi: 10.1200/JCO.2013.50.0322. Epub 2013 Sep 23.


Variation in the availability of cancer drug generics in the United States of America.

Elzawawy AM, Kerr DJ.

Ann Oncol. 2013 Sep;24 Suppl 5:v17-22. doi: 10.1093/annonc/mdt324.


Asymmetric synthesis of (+)- and (-)-pauciflorol F: confirmation of absolute stereochemistry.

Kerr DJ, Miletic M, Manchala N, White JM, Flynn BL.

Org Lett. 2013 Aug 16;15(16):4118-21. doi: 10.1021/ol401752u. Epub 2013 Jul 30.


The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.


Biological markers: Tailoring treatment and trials to prognosis.

Kerr DJ, Shi Y.

Nat Rev Clin Oncol. 2013 Aug;10(8):429-30. doi: 10.1038/nrclinonc.2013.97. Epub 2013 Jun 11. No abstract available.


The reconstruction of narrative identity during mental health recovery: a complex adaptive systems perspective.

Kerr DJ, Crowe TP, Oades LG.

Psychiatr Rehabil J. 2013 Jun;36(2):108-9. doi: 10.1037/h0094978. Review.


Stage II colon cancer.

Church DN, Midgley R, Kerr DJ.

Chin Clin Oncol. 2013 Jun;2(2):16. doi: 10.3978/j.issn.2304-3865.2013.03.03.


Cancer in Africa: supporting advocates to stop the runaway train.

Adamou A, Odedina FT, Torode J, Kerr DJ.

Ann Oncol. 2013 Apr;24(4):855-6. doi: 10.1093/annonc/mdt062. No abstract available.


Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.

Midgley RS, Kerr DJ.

J Clin Oncol. 2013 Apr 20;31(12):1611. doi: 10.1200/JCO.2012.47.2852. Epub 2013 Mar 18. No abstract available.


Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.

Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S; CORGI Consortium; WGS500 Consortium, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I.

Nat Genet. 2013 Feb;45(2):136-44. doi: 10.1038/ng.2503. Epub 2012 Dec 23. Erratum in: Nat Genet. 2013 Jun;45(6):713. Guarino Almeida, Estrella [corrected to Guarino, Estrella].


The TERT variant rs2736100 is associated with colorectal cancer risk.

Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS; Colon Cancer Family Registry.

Br J Cancer. 2012 Sep 4;107(6):1001-8. doi: 10.1038/bjc.2012.329. Epub 2012 Aug 9.


The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE.

Ann Oncol. 2013 Jan;24(1):179-85. doi: 10.1093/annonc/mds246. Epub 2012 Aug 2.


Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.


EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme.

Kennedy RH, Francis A, Dutton S, Love S, Pearson S, Blazeby JM, Quirke P, Franks PJ, Kerr DJ.

BMC Cancer. 2012 May 16;12:181. doi: 10.1186/1471-2407-12-181.


A new approach to highly substituted cyclopentanoids from a concise formal synthesis of (+)-roseophilin.

Kerr DJ, Flynn BL.

Org Lett. 2012 Apr 6;14(7):1740-3. doi: 10.1021/ol300332b. Epub 2012 Mar 28.


Oxazolidinone-promoted, torquoselective Nazarov cyclizations.

Kerr DJ, Miletic M, Chaplin JH, White JM, Flynn BL.

Org Lett. 2012 Apr 6;14(7):1732-5. doi: 10.1021/ol300316a. Epub 2012 Mar 28.


Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate.

Lobachevsky P, Smith J, Denoyer D, Skene C, White J, Flynn BL, Kerr DJ, Hicks RJ, Martin RF.

Int J Radiat Biol. 2012 Dec;88(12):1009-18. doi: 10.3109/09553002.2012.666375. Epub 2012 Mar 22.


Arginine methylation controls growth regulation by E2F-1.

Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, McGouran J, Coutts AS, Kessler B, Kerr DJ, Thangue NB.

EMBO J. 2012 Apr 4;31(7):1785-97. doi: 10.1038/emboj.2012.17. Epub 2012 Feb 10.


Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13.

Spain SL, Carvajal-Carmona LG, Howarth KM, Jones AM, Su Z, Cazier JB, Williams J, Aaltonen LA, Pharoah P, Kerr DJ, Cheadle J, Li L, Casey G, Vodicka P, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Morreau H, van Wezel T, Ruiz-Ponte C, Fernandez-Rozadilla C, Carracedo A, Castells A, Castellvi-Bel S, Dunlop M, Houlston RS, Tomlinson IP.

Hum Mol Genet. 2012 Feb 15;21(4):934-46. doi: 10.1093/hmg/ddr523. Epub 2011 Nov 10.


Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ.

J Clin Oncol. 2011 Dec 10;29(35):4611-9. doi: 10.1200/JCO.2010.32.8732. Epub 2011 Nov 7.


Better value cancer care for the 21st century.

Gray M, Naredi P, Bacon N, Kerr DJ.

Ann Oncol. 2011 Dec;22(12):2541-5. doi: 10.1093/annonc/mdr457. Epub 2011 Nov 2. No abstract available.


Challenges of cancer control in developing countries: current status and future perspective.

Sharma V, Kerr SH, Kawar Z, Kerr DJ.

Future Oncol. 2011 Oct;7(10):1213-22. doi: 10.2217/fon.11.101. Review.


Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

La Thangue NB, Kerr DJ.

Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96. doi: 10.1038/nrclinonc.2011.121. Review.


A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22.

Abulí A, Fernández-Rozadilla C, Giráldez MD, Muñoz J, Gonzalo V, Bessa X, Bujanda L, Reñé JM, Lanas A, García AM, Saló J, Argüello L, Vilella A, Carreño R, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Tomlinson IP, Kerr DJ, Houlston RS, Piqué JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellví-Bel S; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Br J Cancer. 2011 Sep 6;105(6):870-5. doi: 10.1038/bjc.2011.296. Epub 2011 Aug 2.


Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB 3rd, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA.

J Clin Oncol. 2011 Aug 10;29(23):3146-52. doi: 10.1200/JCO.2010.32.5357. Epub 2011 Jul 11.


Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer.

Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, Palles C, Broderick P, Jaeger EE, Farrington S, Lewis A, Prendergast JG, Pittman AM, Theodoratou E, Olver B, Walker M, Penegar S, Barclay E, Whiffin N, Martin L, Ballereau S, Lloyd A, Gorman M, Lubbe S; COGENT Consortium; CORGI Collaborators; EPICOLON Consortium, Howie B, Marchini J, Ruiz-Ponte C, Fernandez-Rozadilla C, Castells A, Carracedo A, Castellvi-Bel S, Duggan D, Conti D, Cazier JB, Campbell H, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Gallinger S, Newcomb P, Hopper J, Jenkins MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah P, Casey G, Houlston RS, Dunlop MG.

PLoS Genet. 2011 Jun;7(6):e1002105. doi: 10.1371/journal.pgen.1002105. Epub 2011 Jun 2.

Supplemental Content

Support Center